Serum levels of mir-128-3p are associated to clinical course and disease activity in multiple sclerosis

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system whose etiology remains unclear. It has been suggested that MS can be triggered by certain viruses; however, human immunodeficiency virus (HIV) infection is associated with reduced incidence of MS. We present the case of a young patient diagnosed with active relapsing-remitting MS whose clinical course substantially improved following HIV infection and treatment. The patient achieved no evidence of disease activity status without any disease-modifying drugs. Both HIV-induced immunosuppression and antiretroviral therapy may have attenuated the clinical course in this patient.

Download Full-text

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis

Journal of Neuroimmunology ◽

10.1016/j.jneuroim.2018.07.011 ◽

2018 ◽

Vol 323 ◽

pp. 73-77 ◽

Cited By ~ 2

Author(s):

Silje Stokke Kvistad ◽

Kjell-Morten Myhr ◽

Trygve Holmøy ◽

Jūratė Šaltytė Benth ◽

Stig Wergeland ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Treatment Response ◽

Serum Levels

Download Full-text

Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis

Multiple Sclerosis Journal ◽

10.1191/1352458506ms1241oa ◽

2006 ◽

Vol 12 (1) ◽

pp. 2-12 ◽

Cited By ~ 37

Author(s):

E Fainardi ◽

R Rizzo ◽

L Melchiorri ◽

M Castellazzi ◽

E Paolino ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Neurological Disorders ◽

Serum Levels ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Concentrations ◽

Intrathecal Synthesis ◽

Soluble Hla ◽

Elisa Technique ◽

Magnetic Resonance Imaging Mri

The aim of this study was to provide further insight into the effective contribution of classical soluble HLA-A, B and C class Ia (sHLA-I) and non-classical soluble HLA-G class Ib (sHLA-G) molecules in immune dysregulation occurring in multiple sclerosis (MS). We evaluated by enzyme-linked immunosorbent assay (ELISA) technique intrathecal synthesis and cerebrospinal fluid (CSF) and serum levels of sHLA-I and sHLA-G in 69 relapsing-remitting (RR), 21 secondary progressive (SP) and 13 primary progressive (PP) MS patients stratified according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also tested, as neurological controls, 91 patients with other inflammatory neurological disorders (OIND) and 92 with non-inflammatory neurological disorders (NIND). Eighty-two healthy volunteers served as further controls for sHLA-I and sHLA-G determinations. An intrathecal production of sHLA-I and sHLA-G detected by specific indexes was significantly more frequent in MS patients than in controls (p<0.01). An intrathecal synthesis of sHLA-I was prevalent in clinically (p<0.02) and MRI active (p<0.001) MS, whereas a CSF-restricted release of sHLA-G predominated in clinically (p<0.01) and MRI stable (p<0.001) MS. sHLA-I levels were low in the serum of clinically active (p<0.001) and high in the CSF of MRI active (p<0.01) MS. Conversely, sHLA-G concentrations were decreased in the serum of clinically stable MS (p<0.01) and increased in the CSF of MRI inactive MS (p<0.001). The trends towards a negative correlation observed between CSF and serum concentrations and intrathecal synthesis of sHLA-I and sHLA-G in patients without evidence of clinical and MRI activity confirmed that intrathecal production and fluctuations in CSF and serum concentrations of sHLA-I and sHLA-G were reciprocal in MS. Our results suggest that, in MS, a balance between classical sHLA-I and non-classical sHLA-G products modulating both MRI and clinical disease activity in opposite directions may exist.

Download Full-text

Soluble MHC class I chain-related protein B serum levels correlate with disease activity in relapsing–remitting multiple sclerosis

Human Immunology ◽

10.1016/j.humimm.2008.01.021 ◽

2008 ◽

Vol 69 (4-5) ◽

pp. 235-240 ◽

Cited By ~ 20

Author(s):

Juan Luís Fernández-Morera ◽

Sandra Rodríguez-Rodero ◽

Carlos Lahoz ◽

Alberto Tuñon ◽

Aurora Astudillo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Mhc Class I ◽

Serum Levels ◽

Class I ◽

Related Protein ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis ◽

Protein B

Download Full-text

A Randomized Controlled Safety Trial of Interferon beta–1a and Oral Cyclophosphamide in MS

International Journal of MS Care ◽

10.7224/1537-2073-4.4.174 ◽

2002 ◽

Vol 4 (4) ◽

pp. 174-182 ◽

Cited By ~ 1

Author(s):

Michael Kaufman ◽

H. James Norton ◽

Gerald Sonnenfeld

Keyword(s):

Multiple Sclerosis ◽

Side Effects ◽

Disease Activity ◽

Interferon Beta ◽

Clinical Course ◽

Randomized Study ◽

Breast Mass ◽

Oral Cyclophosphamide ◽

Randomized Controlled ◽

Acute Side Effects

We evaluated the safety of adding oral cyclophosphamide to interferon beta-1a (IFNβ-1a; Avonex®) in a placebo-controlled randomized study of 24 patients with multiple sclerosis (MS). The clinical course was monitored during nine months of treatment. Treated patients tolerated 150 to 200 mg/m2 of weekly administered cyclophosphamide and IFNβ-1a with few reported side effects. We conclude that oral cyclophosphamide can be added safely to IFNβ-1a without intolerable acute side effects. One death unrelated to treatment occurred. Cholecystitis and a benign breast mass both developed in a single cyclophosphamide-treated participant. Leukopenia and lymphopenia were observed in treated participants. Longer, larger trials testing the efficacy of cyclophosphamide may be appropriate for some individuals with breakthrough disease activity while taking IFNβ-1a. (Int J MS Care. 2002; 4: 174–175, 180–182)

Download Full-text

First trimester interleukin 8 levels are associated with postpartum relapse in multiple sclerosis

Multiple Sclerosis Journal ◽

10.1177/1352458509107009 ◽

2009 ◽

Vol 15 (11) ◽

pp. 1356-1358 ◽

Cited By ~ 18

Author(s):

Rinze F Neuteboom ◽

Evert Verbraak ◽

Jane SA Voerman ◽

Marjan van Meurs ◽

Eric AP Steegers ◽

...

Keyword(s):

Multiple Sclerosis ◽

High Risk ◽

Disease Activity ◽

Serum Levels ◽

First Trimester ◽

Interleukin 8 ◽

Disease Course ◽

Third Trimester ◽

The Third

Pregnancy has an ameliorating effect on multiple sclerosis (MS), but directly after delivery the risk of a relapse is increased. The pro-inflammatory chemokine interleukin 8 is associated with disease activity. We aimed to investigate whether pregnancy-induced fluctuations of interleukin 8 correlate with periods of enhanced and diminished disease activity. Thirty-six women with MS were prospectively studied before, during and after pregnancy. Serum levels of interleukin 8 were significantly decreased during the third trimester (p = 0.03). High first trimester serum levels of interleukin 8 were associated with a high risk of postpartum relapse (p = 0.007). These results help us to further understand the altered disease course during pregnancy.

Download Full-text

Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis

Multiple Sclerosis Journal ◽

10.1191/135248506ms1274oa ◽

2006 ◽

Vol 12 (3) ◽

pp. 294-301 ◽

Cited By ~ 84

Author(s):

E Fainardi ◽

M Castellazzi ◽

T Bellini ◽

M C Manfrinato ◽

E Baldi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cerebrospinal Fluid ◽

Matrix Metalloproteinase ◽

Disease Activity ◽

Neurological Disorders ◽

Serum Levels ◽

Matrix Metalloproteinase 9 ◽

Active Matrix ◽

Magnetic Resonance Imaging Mri ◽

Metalloproteinase 9

In this study, we employed a sensitive activity assay system to measure cerebrospinal fluid (CSF) and serum levels of active matrix metalloproteinase-9 (MMP-9) in 37 relapsing-remitting (RR), 15 secondary progressive (SP) and nine primary progressive (PP) multiple sclerosis (MS) patients, grouped according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also studied, as neurological controls, 48 patients with other inflammatory neurological disorders (OIND) and 48 with non-inflammatory neurological disorders (NIND). To assess active MMP-9/TIMP-1 circuit, CSF and serum levels of MMP-9 tissue inhibitor TIMP-1 were quantified by ELISA in the same patient population. CSF mean levels of active MMP-9, CSF active MMP-9/TIMP-1 ratios and intrathecal active MMP-9 synthesis, as indicated by specific index, were more elevated in MS than in NIND ( P <0.05, <0.02 and <0.02, respectively), serum active MMP-9/TIMP-1 ratio was higher in MS ( P<0.01) and OIND ( P<0.02) than in NIND, and serum TIMP-1 concentrations were lower in MS than in NIND ( P<0.05). More importantly, serum active MMP-9 mean levels, serum active MMP-9/TIMP-1 ratio and intrathecal production of active MMP-9 were increased in MS patients with clinical ( P<0.001, <0.001 and <0.05, respectively) and MRI ( P<0.001, <0.001 and <0.02, respectively) disease activity, whereas CSF mean concentrations of active MMP-9 and CSF active MMP-9/TIMP-1 ratio were enhanced only in MS patients with MRI evidence of disease activity ( P<0.02 and <0.01, respectively). Altogether, these findings suggest that a shift in MMP-9/TIMP-1 balance towards proteolytic activity of MMP-9 could be relevant in MS immune dysregulation. In addition, our results indicate that CSF and serum levels of active MMP-9 may represent a potential surrogate biomarker for monitoring MS disease activity. In particular, serum active MMP-9/TIMP-1 ratio seems to be a very appropriate indicator of ongoing MS inflammation, since it is easily measurable.

Download Full-text